Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial

Peer Review reports

Original Submission
21 Aug 2023	Submitted	Original manuscript
5 Sep 2023	Reviewed	Reviewer Report - Alexander Gough
17 Nov 2023	Reviewed	Reviewer Report - Riaz Qureshi
7 Feb 2024	Author responded	Author comments - Jimmy Belotte
Resubmission - Version 2
7 Feb 2024	Submitted	Manuscript version 2
27 Feb 2024	Reviewed	Reviewer Report - Alexander Gough
3 Mar 2024	Reviewed	Reviewer Report - Riaz Qureshi
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
26 Apr 2024	Editorially accepted
4 May 2024	Article published	10.1186/s13063-024-08142-5

Back to article page